What’s Stopped Me From Buying AstraZeneca Plc Today

Royston Wild considers the investment case for AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today, I am looking at AstraZeneca (LSE: AZN) (NYSE: AZN.US), and deciding whether to add the company to my personal stocks portfolio.

Patent expiration problems continue to gallop on

AstraZeneca’s half-yearly report released this month showed revenues, on a constant exchange rate, fall 8% in January-June to $12.62bn. This in turn drove core operating profit 16% lower to $4.38bn. The effect of patent expiration across many of its key products moderated in the second quarter, although revenues and core operating profit still fell 4% and 10% in the period.

Promisingly, AstraZeneca announced that its product pipeline had added three promising late-stage assets in core therapeutic areas of cardiovascular/metabolism and respiratory diseases”. The company is undergoing significant transformation plans at its R&D operations across Europe in order to compensate for the loss of key patents and undergird future earnings growth.

But the firm seems to be behind many of its rivals such as GlaxoSmithKline in significantly addressing the issue of exclusivity loss and bringing online new earnings drivers. The new product additions are a promising development in the firm’s transformation plan, but with new drugs taking years to hit the shelves from initial testing, investors should be braced for more near-term pain.

Earnings slump predicted to last through 2014

City forecasters expect last year’s 12% earnings slump to remain in vogue well into the medium term. Earnings per share are expected to slip 19% this year, to 335p, before falling a further 6% in 2014 to 316p.

The pharma play currently changes hands on a P/E ratio of 9.7 and 10.3 for 2013 and 2014 respectively, figures anchored around the widely-regarded bargain watermark of 10 times prospective earnings. But in my opinion this simply reflects the dearth of earnings catalysts at the firm and thus strong likelihood for shareholder returns to encounter severe pressure.

Pick up the prescription for bountiful gains

On the dividend front, analysts have pencilled in a full-year payout of 285 US cents for 2013, with a rise to 287 cents expected next year. These payments carry yields of 5.7%, comfortably beating the 3.1% FTSE 100 average and aggregate reading of 2.4% for its pharmaceuticals and biotechnology rivals.

AstraZeneca kept the dividend on hold at 280 cents last year as earnings crumbled, and I believe that future dividends could come under fire should further earnings pressure materialise as expected. In my opinion the pharma giant represents too much of a gamble for investors at present, and I will be waiting for more progress from its product pipeline before I consider parting with my cash.

So although AstraZeneca is not a candidate for the savvy investor’s stocklist at present, I believe that you should check out this exclusive, in-depth report about another FTSE 100 high-income opportunity ready to dispense lucrative shareholder returns.

The blue chip in question offers a prospective dividend yield comfortably north of 5%, and has been declared “The Motley Fool’s Top Income Stock For 2013“! Click here to download the report now — it’s absolutely free and comes with no further obligation.

> Royston does not own shares in AstraZeneca. The Motley Fool has recommended shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Close-up of British bank notes
Investing Articles

I’d buy 1,064 shares of this dividend growth stock for £1,000 a year in passive income

Shares in FTSE 100 conglomerate Bunzl come with a 2% yield at today’s prices. But Stephen Wright thinks this is…

Read more »

Growth Shares

Under 50? Here are 3 monster growth stocks to consider for 2024 and beyond

These US-listed growth stocks could deliver blockbuster gains for long-term investors in the years ahead, says Edward Sheldon.

Read more »

Investing Articles

Here’s how much I’d need to invest in Tesco shares for £100 in monthly passive income

Our writer does not own shares of this supermarket for passive income, but how many would he need to buy…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could £200 of Christmas money be used to start buying shares this month?

Our writer reckons if he was a stock market novice, he could put some Christmas money to work and start…

Read more »

Close-up of British bank notes
Investing Articles

Here’s how I’d aim to build a £250 monthly second income in 2024 – and far beyond!

Our writer thinks buying carefully-chosen dividend shares could help him build a second income over the long term. Here's his…

Read more »

Investing Articles

If I’d put £10k into a FTSE 250 tracker 10 years ago, here’s what I’d have now

UK investors love FTSE 250 tracker funds. But have these products been a good investment over the long term? Edward…

Read more »

Risk reward ratio / risk management concept
Investing Articles

I’d use a Stocks and Shares ISA to invest in low-risk equities and let the passive income roll in

Stephen Wright thinks a Stocks and Shares ISA can be a valuable way of generating tax-efficient passive income even for…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

With no savings at 30, I’d use Warren Buffett’s golden rules to build wealth

Dr James Fox explains how he can use the legendary teachings of Warren Buffett to turn an empty portfolio into…

Read more »